Therapeutic Potential of Selectively Targeting the α

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

35 citing papers in PubMed, 69 citations in OpenAlex.

1. A Comparative Study on Sedation Efficacy Between General and Regional Anesthesia with Dexmedetomidine in Patients Under Maxillofacial Surgery.Current drug metabolism · 2022
   Trial
2. Adjunctive Pharmacotherapy for Major Depressive Disorder with Anxiety Symptoms: from Monoamines to Recent Clinical Evidence.CNS drugs · 2026
   Review
3. Roles of the Cholinergic and Adrenergic Systems in Vagus Nerve Stimulation for the Recovery of Motor Function in Patients with Stroke: Opportunities for Novel Treatments and Rehabilitation.International journal of molecular sciences · 2026
   Review
4. Towards Mechanism-Informed Treatments for Mental Health.Journal of neurochemistry · 2026
   Review
5. Transcutaneous Auricular Vagus Nerve Stimulation for Treating Emotional Dysregulation and Inflammation in Common Neuropsychiatric Disorders.Brain sciences · 2025
   Review
6. The pharmacology underlying the unique antipsychotic efficacy of clozapine.Journal of psychopharmacology (Oxford, England) · 2025
   Review
7. Identification ofMolecules (Basel, Switzerland) · 2025
   Article
8. Preclinical Evidence for the Use of Brexpiprazole + Antidepressant Treatment for Major Depressive Disorder and Post-Traumatic Stress Disorder: A Systematic Review.Neuropsychiatric disease and treatment · 2025
   Review
9. Therapeutic Potential of Dexmedetomidine in Neuropsychiatric Disorders: From the Bench to the Clinic.Current neuropharmacology · 2025
   Review
10. AMPA receptors modulate enhanced dopamine neuronal activity induced by the combined administration of venlafaxine and brexpiprazole.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Article
11. Brexpiprazole: A new option in treating agitation in Alzheimer's dementia-Insights from transgenic mouse models.Neuropsychopharmacology reports · 2024
    Article
12. Temporal Dynamics of Plasma Catecholamines, Metabolic and Immune Markers, and the Corticosterone:DHEA Ratio in Farmed Crocodiles before and after an Acute Stressor.Animals : an open access journal from MDPI · 2024
    Article
13. Exploratory focused pharmacogenetic testing reveals novel markers associated with risperidone pharmacokinetics in Saudi children with autism.Frontiers in pharmacology · 2024
    Article
14. Activation of 5-HT1A Receptors Normalizes the Overexpression of Presynaptic 5-HT1A Receptors and Alleviates Diabetic Neuropathic Pain.International journal of molecular sciences · 2023
    Article
15. G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders.Signal transduction and targeted therapy · 2023
    Review
16. Antihypertensive drugs and brain function: mechanisms underlying therapeutically beneficial and harmful neuropsychiatric effects.Cardiovascular research · 2023
    Review
17. Synergistic anti-depressive effect of combination treatment of Brexpiprazole and selective serotonin reuptake inhibitors on forced swimming test in mice.Neuropsychopharmacology reports · 2023
    Article
18. Preclinical evaluation of new C-11 labeled benzo-1,4-dioxane PET radiotracers for brain α2C adrenergic receptors.European journal of medicinal chemistry · 2022
    Article
19. Bio-behavioural changes in treatment-resistant socially isolated FSL rats show variable or improved response to combined fluoxetine-olanzapine versus olanzapine treatment.IBRO neuroscience reports · 2022
    Article
20. The affinity and selectivity of α-adrenoceptor antagonists, antidepressants and antipsychotics for the human α2A, α2B, and α2C-adrenoceptors and comparison with human α1 and β-adrenoceptors.Pharmacology research & perspectives · 2022
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors at 2 institutions in 2 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as